1 Background 2 Psychiatric disorders are multigenic diseases with complex etiology contributing 3 significantly to human morbidity and mortality. Although clinically distinct, several 4 disorders share many symptoms suggesting common underlying molecular changes 5 exist that may implicate important regulators of pathogenesis and new therapeutic 6 targets. 7 Results 8
10
Consortium, we downloaded the p-values reported for Schizophrenia hits from 1 Supplemental Table 4 , which contained 424 significant GO terms. We used a chi-2 squared test to assess significant overlap between the two groups. Supplemental Table   3 X reports the p-values measured in SZ based on this study along with those calculated 4 in our analysis. 5 EGR1 ChIP-seq peak analysis 6 Narrow peak bed files from optimal IDR thresholded peaks were obtained from the 7 ENCODE data portal (www.encodeproject.org) for EGR1 ChIP-seq data in GM12878, 8 H1-hESC, and K562 cell lines (ENCODE file IDs: ENCFF002CIV, ENCFF002CGW, 9 ENCFF002CLV). Consensus EGR1 peaks were identified by intersecting peaks from all 1 0 three cell lines, which resulted in a final list of 4,121 peaks that were present in each cell 1 1 line (with a minimum overlap of 1bp). The distance from each annotated transcription 1 2 start site (TSS) to the nearest consensus EGR1 peak was computed using TSSs 1 3 annotated in the ENSEMBL gene transfer format (GTF) file used for aligning RNA-seq 1 4 reads (GRCh37_E75). Sets of transcripts uniquely expressed by several brain cell-types were obtained from 1 7 figure 1B in Darmanis et. al [27] . An index for each cell-type was created by finding the 1 8 median normalized expression value for each cell-type associated transcript set. Index values were compared across patient clusters by non-parametric rank sum tests and 2 0 spearman correlation with top principal components. To validate our method, we 2 1 calculated cell-type specific indices from an independent cohort of previously published 2 2 purified brain cells [28, 29] . FPKM-normalized transcript data was obtained from 2 3 11 supplemental table 4 of Zhang et. al. (2014) and cell-type indexes were calculated as 1 described above. To examine index performance in mixed cell populations, we obtained 2 fastq files for neuron and astrocyte-purified brain samples from GEO accession 3 GSE73721 and generated raw count files as described above. We next mixed 4 expression profiles in silico by performing random down-sampling of neuron and 5 astrocyte count levels and summing the results such that mixed populations containing 6 specific proportions of counts from neuron-and astrocyte-purified tissue were 7 generated. For example, to generate an 80/20 neuron to astrocyte mixture, neuron and 8 astrocyte count columns (which started at an equivalent number of 5,759,178 aligned 9 reads) were randomly down-sampled to 4,607,342 and 1,151,836 counts respectively 1 0 and summed across each gene to result in a proportionately mixed population of 1 1 aligned count data simulating heterogeneous tissue. Then we calculated a 1 2 neuron/astrocyte index ratio capable of predicting the in silico mixing weights. Briefly, 1 3 we assumed index values for mixed cell populations were directly proportional to mixing 1 4 weights of their respective purified tissue, thus the predicted cell proportion for a given 1 5 cell type was simply calculated as: To insure cell-type predictive power was unique to indices derived from Darmanis et. al 1 8 transcripts, we generated indices from 10,000 randomly sampled transcript sets of 1 9 equivalent size and examined their performance in predicting in silico mixing weights.
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Mean squared prediction errors (MSE) were calculated for each of the 10,000 null Sections of approximately 100mg of frozen tissue were weighed and homogenized for 2 45 seconds at 6.5M/s with ceramic beads in 1mL of 50% methanol using the MP 3 FastPrep-24 homogenizer (MP Biomedicals). A sample volume equivalent to 10mg of 4 initial tissue weight was dried down at 55 o C for 60 minutes using a vacuum concentrator 5 system (Labconco). Derivatization by methoximation and trimethylsilylation was done as 6 previously described [30] . 7 We analyzed technical replicates of each tissue sample, in randomized order.
8

GCxGC-TOFMS analysis 9
All derivatized samples were analyzed on a Leco Pegasus 4D system (GCxGC-1 0 TOFMS), controlled by the ChromaTof software (Leco, St. Joseph, MI). Samples were 1 1 analyzed as described previously [30] with minor modifications in temperature ramp. analysis similar to that of a previously described method [33] was first performed on 2 1 metabolite and transcript data separately. Our method builds on the principle described 2 2 13 by Subramanian that implements a one-tailed Wilcox test to identify pathways enriched 1 for low p-values. Instead of just accounting for enrichment at the gene level, we use 2 metabolite or transcript p-value ranks within each pathway compared to remaining non-3 pathway metabolites or transcripts with a one-tailed Wilcox test to test the hypothesis 4 that elements of a given pathway may be enriched for lower p-value ranks than 5 background elements. Metabolite and transcript p-values were subsequently combined 6 to provide an integrated enrichment significance p-value using Fisher's method.
7
Pathways had to contain greater than 5 genes and 1 metabolite measured in our 8 dataset to be included in the analysis. Supplemental table 10 lists p-values for enriched 9 pathways based on genes, metabolites or combined. 
Region-specific gene expression in control and psychiatric brain tissue 1 2
We collected post-mortem human brain tissue, associated clinical data, including age, 1 3 sex, brain pH, and post-mortem interval (PMI), and cytotoxicology results (Tables S1-2) 1 4 for matched cohorts of 24 patients each diagnosed with SZ, BPD, or MDD, as well as 1 5 24 control individuals with no personal history of, or first-degree relatives diagnosed 1 6 with, psychiatric disorders. Importantly, to limit the effect of acute patient stress at the 1 7 time of death as a potential confounder we included only patients with an agonal factor 1 8 score of zero and a minimum brain pH of 6.5 [19] . Using RNA-seq [22], we profiled gene 1 9 expression in three macro-dissected brain regions (AnCg, DLPFC, nAcc). After quality 2 0 control, we analyzed 57,905 ENSEMBL transcripts in a total of 281 brain samples 2 1 (Table S3 ). To examine heterogeneity across brain regions and subjects, we performed a principal 1 component analysis (PCA; Figure S1A reported post-mortem brain RNA sequencing studies [15], we found several principal 7 components to be highly correlated with quality metrics including the percentage of 8 reads uniquely aligned and percentage of reads aligned to mitochondrial sequence 9 (absolute Rho>0.5, FDR<1E-16, Table S4 ). To reduce the potentially confounding 1 0 effects of sample quality, we repeated the PCA on expression data normalized to the 1 1 percentage of reads uniquely aligned for each sample and found that global disease-1 2 specific expression differences were significantly reduced (Figures S1C and S2D-I).
1 3
Disease-specific gene expression in control and psychiatric brains 1 4
We next applied DESeq2 [1], a method for differential analysis of sequence read count 1 5 data, to identify genes differentially expressed across disorders within each brain region FDR<0.05, Figure 1A ). Pathway enrichment analysis of differentially expressed genes 1 9 between SZ and CTL patients revealed 935 gene ontology (GO) terms with an 2 0 FDR<0.05 (Table S5 ) (122 GOCC, 159 GOMF, and. 654 GOBP). Significant GO terms 2 1 fall into the broad categories of synaptic function and signaling (e.g. neurotransmitter 2 2 transport, ion transport, calcium signaling) ( Figure S3 ). These terms overlap significantly 2 3 15 with those identified by the Psychiatric Genomics Consortium in their analysis of GWAS 1 implicated genes [34] with 68 GO terms meeting a p-value cutoff of <0.05 in both 2 datasets (p<0.0001, Chi-square test). Additionally, nine genes were differentially 3 expressed between SZ and CTL individuals in DLPFC. Three of these were also 4 identified in AnCg: SST, PDPK2P and KLHL14. No transcripts had an FDR<0.05 when 5 comparing BPD or MDD samples to CTLs in any brain region, or comparing SZ and 6 CTL tissues in nAcc (Table S6 ). To examine potential common gene expression 7 patterns between the psychiatric disorders, we performed pair-wise correlation 8 calculations of all transcript log 2 fold changes for each disorder versus controls in each 9 brain region. Of the nine case-control comparisons (for three regions and three 1 0 diseases), a particularly strong correlation is observed between BPD and SZ compared 1 1 to either SZ or BPD and MDD in each brain region ( Figure 1B ). In the AnCg, BPD and 1 2 SZ share 1,020 common genes differentially expressed at an uncorrected DESeq2 P-1 3 value<0.05 compared to only 248 and 143 genes shared between MDD and SZ or BPD 1 4 respectively ( Figure 1C ). This strong overlap between BPD and SZ (Fisher's exact p-1 5 value<1E-16) indicates that although expression changes are weaker in BPD they 1 6 follow a trend similar to those identified in SZ.
7
Because previous post-mortem analyses have been limited by, and are particularly 1 8 vulnerable to, biases inherent to examining a single patient cohort, we sought to 1 9 generate a robust set of SZ associated transcripts by validating our observed 2 0 expression changes in an independent cohort. To accomplish this, we examined gene Table S7 ). The magnitude and 1 direction of change in significant transcripts in the Pritzker dataset were highly 2 correlated with the SNCID dataset (Rho=0.202, P<1E-16), particularly in transcripts that 3 met an FDR<0.05 cutoff (Rho=0.812, P<1E-16; Figure 1D ). We performed hierarchical 4 clustering of SZ and CTL samples in the SNCID validation cohort using the 1,003 5 transcripts differentially expressed between SZ and CTL in the Pritzker dataset (P<0.05, 6 Figure 1E ), and found these transcripts successfully distinguished the two disease 7 groups with only 5 out of 27 SZ and 2 out of 26 CTL samples misclassified.
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Of particular interest are a group of 5 genes significant at a FDR<0.05 in both cohorts 9 that includes a nearly 2-fold decrease in expression of the transcription factor EGR1 1 0 (Table S7A, Figure 2A ). Quantitative PCR (qPCR) validation of the transcript confirmed 1 1 reduced EGR1 expression in SZ samples ( Figure 2B ). EGR1, a zinc finger transcription 1 2 factor, has been recently implicated in SZ by a GWAS study [6] , thus we sought to 1 3 investigate its role as a potential driver of the transcriptional changes observed in the 1 4
AnCg of SZ patients using publicly available genome-wide occupancy data from the 1 5 ENCODE consortium (https://www.encodeproject.org). To obtain high confidence EGR1
1 6 binding sites we intersected chromatin immunoprecipitation sequencing (ChIP-Seq) 1 7 peaks derived from the H1-hESC, K562, and GM12878 cell lines. We found that 1 8 transcripts whose transcription start sites (TSSs) were within 1kb of an EGR1 binding 1 9 site had significantly lower DESeq2 P-values (Wilcox P=9.68E-5) and significantly more 2 0 negative log2 fold changes (SZ/CTL, Wilcox P=7.69E-15) than transcripts whose TSSs 2 1 were greater than 1kb from an EGR1 binding site. A monotonic decrease in this effect 2 2 17 was observed as the distance threshold used for this comparison was increased from 1 1kb to 50kb ( Figure 2C ). In addition to dysregulation of broadly acting transcription factors, another mechanism 4 that can drive large-scale transcriptional changes in bulk tissue is alterations in 5 constituent cell type proportions. Previous studies have observed decreases in neuron 6 density and increased glial scarring in psychiatric disorders [35, 36] . To test for signs of 7 these alterations in our data set we examined the expression of cell type-specific 8 transcripts identified using data from a single cell RNA sequencing study that identified 9 transcripts capable of classifying individual cells into the major neuronal, glial, and 1 0 vascular cell-types in the brain. We generated cell type indices using the median of compared to controls ( Figures 3A-B ). Other cell-type indices were not significantly 2 2 different between psychiatric patients and controls ( Figure S5 ). Further supporting a 2 3 18 decrease in neuronal gene expression, we found a significant negative correlation 1 between transcript expression in patient brains relative to control brains and the degree 2 of neuron specificity (fold enrichment of neuron expression over other cell types) in SZ 3 and BPD (rho -0.50 and -0.41, P<1E-16, SZ shown in Figure 3C ).
4
Transcriptomic changes reflected in altered metabolomic profiles 5 To assess the biochemical consequences of expression changes, we used 2D-GCMS 6 to measure metabolite levels in 86 of the AnCg samples (sufficient tissue was 7 unavailable for 10 samples). We measured and identified 141 unique metabolites ( Table   8 S8). Similar to our transcript analysis, metabolite levels (Table S9 ) successfully 9 differentiated SZ and BPD patients from CTLs (Figures 4A-B) , while MDD metabolite 1 0 profiles were very similar to CTLs ( Figure S6 ). Several of the most significant synaptic and neurotransmitter signaling ( Figure S7 , Table S10 ). Here, we describe a large transcriptomic dataset across three brain regions (DLPFC, 1 AnCg, and nAcc) in SZ, BPD, and MDD patients, as well as CTL samples matched for 2 agonal state and brain pH. In MDD, we do not identify any transcripts that meet 3 genome-wide significance for differential expression between cases and controls in any 4 brain region. This finding agrees with previous post-mortem RNA-seq studies [39], 5 however sample size and the choice of brain regions examined likely contributed to our 6 inability to replicate results from previous non-transcriptome wide sequencing based 7 approaches comparing MDD to CTL in post-mortem brain [40] . One limitation of our 8 study is that females are underrepresented at a rate of about 5:1. This reflects the 9 increased chance of accidental death among males [41] , but limits us in our ability to 1 0 make more general conclusions about these disorders and to address known 1 1 differences between the sexes as they relate to these disorders. We also do not have 1 2 information on the smoking status for our cohort, which is an important covariate as 1 3 smoking rates are higher among patients with psychiatric disorders and smoking has 1 4 been demonstrated to effect gene expression [42, 43] . Another potential limitation 1 5 inherent to post-mortem cohort analyses is accounting for patient drug use. As detailed 1 6 in supplemental table 2, patient toxicology reports were positive for several prescribed 1 7 and illicit drugs that were not present in CTL samples. As this is a bias inherent to 1 8 psychiatric patients it is impossible to disentangle from non-treatment related disease 1 9 patterns in a post-mortem analysis. Another important limitation of post-mortem RNA-sequencing studies is RNA quality.
1
We found a significant proportion of variation in our data to be associated with multiple 2 2 alignment quality metrics. Significant effort went into controlling for potential sources of 2 3 20 bias due to differences in RNA quality. We only included tissue from patients with an 1 agonal score of 0 and who had a brain pH of 6.5 or greater. We also controlled for brain 2 pH, post-mortem interval, and alignment quality in all differential expression analyses.
3
Our study, as well as future post-mortem studies, could be improved by directly 4 measuring RNA quality at the time of sample preparation (e.g. RNA integrity number 5 (RIN)). Despite these caveats, we believe our data do yield new insights that contribute 6 to our growing understanding of these disorders.
7
The most dramatic gene expression signals we observed were brain region-specific.
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The majority of disease-associated expression differences were seen in the AnCg of SZ 9 compared to CTL patients. The AnCg has been associated with multiple disease-1 0 relevant functions, including cognition, error detection, conflict resolution, motivation, 1 1 and modulation of emotion [44] [45] [46] . We observed a striking overlap in SZ-and BPD-1 2 associated expression changes consistent with previous findings [37, 47] .
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One of the more intriguing transcripts significantly down regulated (FDR<0.05) in both 1 4 cohorts of SZ patients was the zinc finger transcription factor, EGR1. We provide 1 5 evidence that this factor may be driving a large proportion of variation in SZ patients as 1 6 transcripts near consensus EGR1 binding sites tend to have decreased expression in 1 7 SZ patients. Down regulation of EGR1 has been previously described in the prefrontal 1 8 cortex of post-mortem brain samples from SZ patients [48, 49] . EGR1 has also 1 9 previously been associated with several phenotypes relevant to psychiatric disorder antipsychotics [52], and has recently been described as part of a transcription factor-2 2 miRNA co-regulatory network capable of acting as a biomarker in peripheral blood cells 2 3 21 (PBCs) for SZ [53] . In mice, loss of EGR1 has linked to neuronal loss in a model of 1 Alzheimer's Disease [54] . EGR1 is also important for regulation of the NMDA Receptor 2 pathway, which is critical for synaptic plasticity and memory formation and has been 3 implicated in SZ in humans [55] . We believe a more detailed examination of genome-4 wide EGR1 occupancy in post-mortem brain tissue or cultured neurons could yield 5 additional information and assessment of the functional consequences of EGR1 6 perturbation is required to confirm this factor's role in SZ pathogenesis. 7 We also see evidence for depletion of neuron-specific transcripts and increased levels 8 of astrocyte-specific transcripts in SZ and BPD patients. This observation is further 9 supported by metabolomic analysis of the AnCg, which found a concordant decrease in 1 0 GABA levels in BPD and SZ individuals. Neuronal depletion has been previously 1 1 described in SZ [35, 36] . Insufficient tissue remains from our patient cohort to validate 1 2 computational cell type predictions immunohistochemically, however our data strongly differences between disease cohorts and to identify which transcriptional changes occur 2 0 in conjunction with, and independent of, those differences.
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We observed greatly reduced or no significant expression differences in the DLPFC and 2 2 nAcc, which contradicts several previous studies [56, 57] . We do not intend to claim that 2 3 22 no transcriptional changes occur in these brain regions as our study was designed to 1 broadly compare transcriptional alterations across multiple brain regions in multiple 2 psychiatric disorders, thereby sacrificing exceptional sample sizes in any single disorder 3 in any specific brain region. However, our data does suggest that of the regions we 4 tested, the strongest transcriptional changes occur in the AnCg of SZ patients.
5
Moreover, this data provides a useful resource for future studies facilitating the testing 6 of preliminary hypotheses or validation of significant findings. Our study provides several meaningful and novel contributions to the understanding of 9 psychiatric disease. We provide a well-annotated data set that has the potential to act 1 0 as a broadly applicable resource to investigators interested in molecular changes in 1 1 multiple psychiatric disorders across multiple brain regions. We have conducted an 1 2 extensive characterization of the molecular overlap between SZ and BPD at the 1 3 transcript and metabolite level across multiple brain regions. We provide a high 1 4
confidence set of genes differentially expressed between SZ and CTL patients utilizing 1 5 two independent cohorts and highlight down regulation of EGR1 as a potential driver of 1 6 broader scale transcription changes. We also establish that a significant proportion of 1 7 transcriptome variation within SZ and BPD cohorts is correlated with expression 1 8 changes in previously identified cell type-specific transcripts. Research Consortium) under IRB approval (UCI 88-041, UCI 97-74). The datasets supporting the conclusions of this article are available in the GEO 1 repository, GSE80655. 
